# Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients

> **NCT05914857** · PHASE2 · UNKNOWN · sponsor: **Yangjin** · enrollment: 120 (estimated)

## Conditions studied

- Prediabetic State
- Impaired Fasting Glucose
- Impaired Glucose Tolerance

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab
- **BEHAVIORAL:** lifestyle interventions

## Key facts

- **NCT ID:** NCT05914857
- **Lead sponsor:** Yangjin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-20
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05914857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05914857, "Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05914857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*